Quarterly Result28 May 2025, 02:40 pm
Supriya Lifescience Delivers Record-Breaking FY25 with 22% Revenue Growth
AI Summary
Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in APl manufacturing, has reported a 22% year-over-year increase in revenue, reaching Rs. 696.48 crore in FY25. The company's Q4 PAT rose 38.4%, backed by a 16.4% revenue growth and expansion in EBITDA margin. The company's focus on high-value therapeutic segments, deeper penetration in regulated markets, and strengthened backward integration continue to drive its performance.
Key Highlights
- Supriya Lifescience reported a 22% year-over-year increase in revenue, reaching Rs. 696.48 crore in FY25
- The company's Q4 PAT rose 38.4%
- EBITDA for FY25 stood at Rs. 260.80 crore, with an EBITDA Margin of 37.4 %
- Profit after Tax for FY25 stood at Rs. 187.96 crore, with a growth of 57.8%
- Q4 revenue grew by 16.4% to Rs. 184.11 crore, while PAT rose by 38.4% to Rs. 50.38 crore